Key result
Recombinant tissue-type plasminogen activator was administered to three pregnant women with prosthetic mitral valve thrombosis, with outcomes detailed in the full text.
Why the study?
Does recombinant tissue-type plasminogen activator improve outcomes in pregnant women with prosthetic mitral valve thrombosis?
Case Report (n=3)
Does recombinant tissue-type plasminogen activator improve outcomes in pregnant women with prosthetic mitral valve thrombosis?
This case series reports on the use of recombinant tissue-type plasminogen activator for treating prosthetic mitral valve thrombosis during pregnancy, a setting where data is scarce.
No takes yet. Share an insight, caveat, or question.
May guide individualized decisions for rare prosthetic valve thrombosis in pregnancy; leaves open safety and efficacy pending prospective data.
Özer et al. (2009) conducted a case report in Prosthetic mitral valve thrombosis during pregnancy (n=3). Recombinant tissue-type plasminogen activator was evaluated. Recombinant tissue-type plasminogen activator was administered to three pregnant women with prosthetic mitral valve thrombosis, with outcomes detailed in the full text.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: